WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Tuesday, September 18, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email


Global Acute Heart Failure (AHF) Therapeutics Market 2015-2022: Strategic Business Report 2018 - Market Drivers, Trends & Issues
Wednesday, July 11, 2018

DUBLIN, July 11, 2018 /PRNewswire/ --

The "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Next Generation Sequencers in US$ Thousand.

The Global market is additionally analyzed by the following End-Use Segments:

    --  Pharmaceutical/Biotech
    --  Industrial
    --  Government/Academia

The report profiles 93 companies including many key and niche players such as:

    --  Bayer AG (Germany)
    --  Bristol-Myers Squibb Company (USA)
    --  Cardiorentis AG (Switzerland)
    --  CVie Therapeutics Limited (Taiwan)
    --  Cytokinetics, Inc. (USA)
    --  Merck & Co. (USA)
    --  Novartis AG (Switzerland)
    --  Orion Corporation (Finland)
    --  PhaseBio Pharmaceuticals, Inc. (USA)

Key Topics Covered

1. INDUSTRY OVERVIEW
Market Outlook
Sizing the AHF Market
Acute Heart Failure
An Overview of the Disease and Available Therapeutics
Diuretics and Vasodilators
The First Line Therapy for AHF
Other Known Drugs for AHF
Lower Efficacy Thwarts Use

2. MARKET DRIVERS, TRENDS & ISSUES
Conventional Therapies Leave Considerable Unmet Needs
Novel Treatments Offer a Ray of Hope
Key AHF Therapeutics in the Pipeline
Serelaxin Nears Trial Readout form RELAX-AHF-2
Ularitide
A Novel Drug in Development for AHF
The Litany of Drug Failures Expands, Emphasis on Prevention Grows
Other Promising Drugs under Development
Research Findings
Kidney Dysfunction
Predictor of Acute Heart failure
Genetic Influence on Heart Disease among African Americans
Higher Body Mass Index
A Key Risk Factor for AHF
Supplemental Oxygen Therapy May not be for All Cases of AHF
Macro Growth Drivers
Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
CVD: Fast Facts
Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics

3. TREATMENT OF ACUTE HEART FAILURE (AHF)

4. ACUTE HEART FAILURE - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS
Types of AHF
Causes of AHF
Coronary Heart Disease
Cardiomyopathy
High BP
Damaged Heart Valves
Patho-Physiology of AHF
Signs and Symptoms
Low Output
Fluid Overload/Congestion
Left-Sided Failure
Right-Sided Failure
Biventricular Failure
Diagnosis
Classification of AHF
Left Side and Right Side
Systolic Dysfunction and Diastolic Dysfunction
Backward and Forward Failure
Low-Output Heart Failure and High-Output Heart Failure
Functional Classification
Phases of Evaluation and Management of AHF Patients
Early/Initial Phase
In-Hospital Phase
Pre-Discharge Phase
Early Post-Discharge Phase

5. RECENT INDUSTRY ACTIVITY
Capricor Terminates Licensing Deal for Cenderitide with Mayo Clinic
Renova Acquires Stresscopin from Janssen
Cytokinetics to Sell Part of Potential Royalty on omecamtiv mecarbil to Royalty Pharma
CVie Therapeutics Enrolls First Patient for Phase 2b Clinical Trial of Istaroxime
ScinoPharm and CVie Therapeutics Collaborate for New AHF Drug
Trevena's TRV027 Fails to Meet Clinical Study Endpoints
NIH Awards SBIR Grant to Madeleine Pharmaceuticals for Clinical Development of Vastiras
Cardiorentis Raises Funds to Support Competition of Phase III Trials on Ularitide for ADHF
FDA Grants Fast Track Designation to Cardiorentis' Ularitide
Bristol-Myers Squibb Completes Acquisition of Cardioxyl
Cardiorentis Completes Enrollment in Phase III Trial of Ularitide
Capricor Therapeutics Completes Enrollment for Phase II Trial of Cenderitide
Cardiorentis Enters into Collaboration with Roche
Capricor Enters into Agreement to Acquire Patent Rights of Natriuretic Peptides from Medtronic
Cardiorentis Enters into 45 million Financing Agreement with HC Royalty
USPTO Grants Patent to Trevena's TRV027
FDA Declines Approval for Novartis' Serelaxin

6. FOCUS ON SELECT PLAYERS
Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Cardiorentis AG (Switzerland)
CVie Therapeutics Limited (Taiwan)
Cytokinetics, Inc. (USA)
Merck & Co. (USA)
Novartis AG (Switzerland)
Orion Corporation (Finland)
PhaseBio Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 34 (including Divisions/Subsidiaries 35)

    --  The United States (18)
    --  Japan (2)
    --  Europe (10)
        --  Germany (2)
        --  The United Kingdom (2)
        --  Italy (1)
        --  Rest of Europe (5)
    --  Asia-Pacific (Excluding Japan) (5)

For more information about this report visit https://www.researchandmarkets.com/research/kqgx2h/global_acute?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-acute-heart-failure-ahf-therapeutics-market-2015-2022-strategic-business-report-2018---market-drivers-trends--issues-300679451.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Philips PDS and SMiT to offer the first VSecure CAM Module | Sep 18, 2018
Nav New Employee Experience 1.5 Day Sprint Yields Rapid Results Through Design Thinking and Journey Mapping | Sep 18, 2018
Nav All About Inc. Launches Global Site "Local Creators' Market" to Connect Japan to World through Local Craftwork under Government Support | Sep 18, 2018
Nav DucMeta Wins Sales Award for Outstanding Performance | Sep 18, 2018
Nav Federal Government Contract Growth Leader SBG Technology Solutions, Inc. Seeks Lead Solution Architect | Sep 18, 2018
Nav Global Strategic Evaluation of Precision Medicine Markets 2016-2026 & Country Analysis for Emerging Opportunities | Sep 18, 2018
Nav BizBash Unveils 2018 List of Top 100 Events in the United States and Canada | Sep 18, 2018
Nav Quantum Metric Raises $25M in Funding to Further Disrupt Real-Time Digital Intelligence Analytics Market | Sep 18, 2018
Nav Foxconn Interconnect Technology, Ltd. to Showcase 400 Gbps Interconnect Solutions at ECOC 2018 | Sep 18, 2018
Nav Salesforce Named a Leader in B2C Commerce Suites by Independent Research Firm | Sep 18, 2018
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News